Billerica, MA and Madison, WI April 14, 2003 Bruker Daltonics and Bruker AXS have agreed to a merger, with the goal of forming a leading tools supplier for life science and materials research that has an emphasis on advancing proteomics.
Under the agreement, Bruker AXS will merge into Bruker Daltonics, and the company name will be changed to Bruker BioSciences. The two companies will continue to operate under their existing names as subsidiaries of Bruker BioSciences.
The combined company will have mass spectrometry and x-ray analysis technology platforms to provide a combination of complementary systems for proteomics. Bruker Daltonics’ mass spectrometry-based protein analysis systems is used in expression proteomics studies, including protein identification, de novo sequencing, as well as the detection and localization of post-translational modifications. It is complemented by Bruker AXS’ X8 series of x-ray crystallography systems for structural proteomics, which can give detailed three-dimensional structural information on proteins and on how proteins bind to other proteins, to DNA, or to small molecules.
The combined product offerings also support other applications in the life sciences, in advanced materials research, in industrial analysis, as well as in chemical and biological detection for defense and homeland security.
“We believe that merging the two affiliated companies enhances our critical mass competitively and takes full advantage of the complementary nature of our technologies and product lines in the attractive proteomics market," says Frank Laukien, PhD, president and CEO of Bruker Daltonics.
“We are excited about this merger, as it allows the combined company to fully leverage its unique competitive advantages, its complementary technologies, as well as its much larger combined international distribution, sales and service organization," says Dr Martin Haase, president and CEO of Bruker AXS.